

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/620,052	07/14/2003	Yasumichi Hitoshi	7946-79800-01	
74839 Klarouist Spar	7590 12/06/2007 kman LLP	EXAMINER		
Klarquist Sparkman, LLP 121 SW Salmon St			HALVORSON, MARK	
Floor 16 Portland, OR 9	97204		ART UNIT	PAPER NUMBER
			1642	
			MAIL DATE	DELIVERY MODE
		•	12/06/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action

Application No.	Applicant(s)
10/620,052	HITOSHI ET AL.
Examiner	Art Unit
Mark Halvorson	1642

Before the Filing of an Appeal Brief	Examiner	Art Unit	T			
	Mark Halvorson	1642				
The MAILING DATE of this communication appe	ears on the cover sheet with the d	orrespondence add	ress			
THE REPLY FILED 20 November 2007 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.				
 The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods: The period for reply expiresmonths from the mailing 	wing replies: (1) an amendment, aff stice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mo	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejecti	on.			
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7. Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	06.07(f). on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	36(a) and the appropria of the fee. The approprinally set in the final Offite of the final rejection, or	te extension fee iate extension fee ce action; or (2) as even if timely filed,			
 The Notice of Appeal was filed on 7/20/2007. A brief in condate of filing the Notice of Appeal (37 CFR 41.37(a)), or a appeal. Since a Notice of Appeal has been filed, any reply AMENDMENTS 	ny extension thereof (37 CFR 41.3	7(e)), to avoid dismis:	sal of the			
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below);						
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims.						
		ected claims.				
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1 4. The amendments are not in compliance with 37 CFR 1.12	,		(DTOL 224)			
		mpilant Amendment (PTOL-324).			
 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 						
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided that the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) results to the proposed amendment(s): a) how the new or amended claims would be rejected is provided to the proposed amendment(s): a) how the new or amended claims would be rejected is provided to the proposed amendment(s): a) how the new or amended claims would be rejected is provided to the proposed amendment(s): a) how the new or amended claims would be rejected is provided to the proposed amendment (s): a) how the new or amended claims would be rejected is provided to the proposed amendment (s): a) how the proposed amen	⊠ will not be entered, or b) □ wil vided below or appended.	l be entered and an e	xplanation of			
Claim(s) rejected: <u>1,2,7, 16 and 18</u> . Claim(s) withdrawn from consideration: <u>3-6,17 and 19-22</u> . <u>AFFIDAVIT OR OTHER EVIDENCE</u>	•					
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	t before or on the date of filing a No d sufficient reasons why the affidav	otice of Appeal will <u>no</u> it or other evidence is	t be entered necessary and			
2. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).						
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•	•			
11. The request for reconsideration has been considered but		condition for allowan	ce because:			
12. ☐ Note the attached Information Disclosure Statement(s). (13. ☐ Other:	PTO/SB/08) Paper No(s)					
		/Misook Yu/ Primary Examiner, /	Art Unit 1642			

Advisory Action Before the Filing of an Appeal Brief

Continuation of 3. NOTE: The amendments to the claims, replacing cell cycle arrest with cell proliferation and deleting all but the A549 transformed cell lines raise new issues that would require further consideration.